Darolutamide Plus ADT and Radiation Therapy Reduces Metastasis Risk in High-Risk Prostate Cancer

• Men with very high-risk prostate cancer had a lower risk of metastasis with intensified treatment.
• The intensified treatment included darolutamide (Nubeqa), androgen deprivation therapy (ADT), and radiation therapy (RT).
• The randomized trial showed a significant reduction in the risk of metastasis.
• The combination therapy reduced the risk of metastasis or death by 58% in high-risk prostate cancer patients.
• The findings were presented at ESMO 2026.